MMS350: A Novel Bifunctional Sulfoxide with Radioprotective Effects

This technology comprises bifunctional compounds based on oxetane-substituted sulfoxides, sulfides, and sulfones that serve dual roles as radiation protectors/mitigators and aqueous solubility enhancers for organic compounds. The compounds feature a core structure where a sulfoxide, sulfide, or sulfone group is connected to oxetane rings with variable substituents, and in some cases, nitrogen atoms replace the oxygen in the ring. The synthesis of the lead compound, MMS350, involves a multi-step process starting from 3-tosyloxymethyl-3-methyloxetane, progressing through a sulfide intermediate, and final oxidation. This molecule has been shown to improve the solubility of drugs while also demonstrating low toxicity and protective effects against various types of radiation-induced damage.

Description

This technology is differentiated by its unique combination of enhanced solubility and effective radiation protection in a single molecular framework. Unlike traditional solubilizers such as DMSO, MMS350 operates via cosolvent properties and exhibits a favorable log P value of -0.87, ensuring better water compatibility. Its dual-action mechanism not only mitigates radiation damage but also improves drug formulation, making it a versatile tool in both pharmaceutical development and radiation therapy applications.

Applications

- Pharmaceutical solubility enhancer
- Radiation countermeasure treatment
- Drug formulation adjuvant
- Radiation damage mitigator

Advantages

- Enhances aqueous solubility of poorly soluble drugs, outperforming traditional solvents like DMSO.
- Acts as a dual-purpose agent that protects against and mitigates radiation-induced damage.
- Demonstrates a low toxicity profile in both in vitro and in vivo studies.
- Offers versatility in chemical structure, allowing for varied substitutions and optimized performance.
- Facilitates improved drug delivery and more reliable high-throughput screening in pharmaceutical development.

IP Status

https://patents.google.com/patent/US9546144B2

Quick Facts:
Reference Number
02601
Technology Type
Therapeutic Modality
Technology Subtype
Small Molecule
Therapeutic Areas
Oncology
Lead Inventor
Peter Wipf
Department
Chemistry
All Tech Innovators
Michael W. Epperly Ph.D.Joel S. Greenberger M.D.Melissa M. SprachmanPeter Wipf
Date Submitted
2011-10-20